Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3726 - Patterns of progression in metastatic melanoma patients treated with Braf and Mek inhibitors: an Italian Melanoma Intergroup (IMI) study


10 Sep 2017


Poster display session


Riccardo Marconcini


Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377


R. Marconcini1, E. Marra2, F. De Rosa3, L.S. Stucci4, L. Orgiano5, S. Ribero2, F. Bloise1, A. Antonuzzo1, A. Falcone1

Author affiliations

  • 1 Oncology Department, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 2 Department Of Medical Sciences, Dermatologic Clinic, University of Turin, Turin/IT
  • 3 Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori, IRST IRCCS, meldola/IT
  • 4 Medical Oncology Unit, University of Bari, Bari/IT
  • 5 Oncology Department, Azienda Ospedaliero Universitaria di Cagliari, 9042 - Monserrato/IT


Abstract 3726


Patterns of progression after BRAF+MEK inhibitors (I) could help clinicians in understanding the best treatment strategy among the multiple available options in the BRAFv600 melanoma setting. We analysed outcomes in patients (pts) treated with BRAF+MEK I to characterize pts with rapid progression.


In this multicenter retrospective analisis, 164 consecutive pts affected by BRAFv600 metastatic melanoma and treated with BRAF+MEK I from February 2012 to April 2017 were included.


Overall, 164 patients were enrolled. Baseline LDH was elevated in 68 (41%) pts, baseline number of metastatic organs were 1, 2, 3 and more in 52 (32%), 52 (32%), 29 (18%), and 32 (19%) pts. BRAF+MEK I administered were dabrafenib+trametinib in 151 pts and vemurafenib+cobimetinib in 13 pts, and they were adiministered in first line in 129 (79%) pts. Best response was CR, PR, SD and PD in 27 (16%), 87 (53%), 17 (10%) and 27 (16%) pts. On cutoff date, progression was observed in 104 (63%) pts; 60 (37%) pts still on treatment. mPFS was 9,83 (1-54,7+) months: significant difference in PFS was showed in pts with normal baseline LDH or high LDH (13.2 vs 6.3 months, p 


DR and extension of progression during BRAF+MEK I are factors that can be useful to identify pts with lower OS after progression, in addiction to known parameters like LDH and baseline number of metastatic organs.

Clinical trial identification

Legal entity responsible for the study





R. Marconcini: Received payment for consultancy and honoraria for speaking from Bristol-Myers Squibb, MSD, Roche, Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.